CL2016000726A1 - Derivados de 4-azaindol - Google Patents

Derivados de 4-azaindol

Info

Publication number
CL2016000726A1
CL2016000726A1 CL2016000726A CL2016000726A CL2016000726A1 CL 2016000726 A1 CL2016000726 A1 CL 2016000726A1 CL 2016000726 A CL2016000726 A CL 2016000726A CL 2016000726 A CL2016000726 A CL 2016000726A CL 2016000726 A1 CL2016000726 A1 CL 2016000726A1
Authority
CL
Chile
Prior art keywords
azaindole derivatives
machrm1
demence
acetilcoline
azaindol
Prior art date
Application number
CL2016000726A
Other languages
English (en)
Inventor
Andrew Payne
Pineiro Jose Luis Castro
Louise Michelle Birch
Afzal Khan
Alan James Braunton
James Edward Kitulagoda
Motohiro Soejima
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of CL2016000726A1 publication Critical patent/CL2016000726A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPUESTOS DERIVADOS DE 4-AZAINDOL O UNA SAL DE LOS MISMOS, MODULADORES DEL RECEPTOR DE ACETILCOLINA MUSCARINICO M1 (MACHRM1); COMPOSICION FARMACEUTICA QUE LOS COMPRENDE; Y METODOS PARA EL TRATAMIENTO SINTOMATICO DEL DETERIORO COGNITIVO EN LA DEMENCIA DE TIPO ALZHEIMER (AD) Y EN LA DEMENCIA CON CUERPOS DE LEWY (DLB).
CL2016000726A 2013-10-01 2016-03-29 Derivados de 4-azaindol CL2016000726A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1317363.8A GB201317363D0 (en) 2013-10-01 2013-10-01 Novel compounds

Publications (1)

Publication Number Publication Date
CL2016000726A1 true CL2016000726A1 (es) 2016-09-23

Family

ID=49585123

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000726A CL2016000726A1 (es) 2013-10-01 2016-03-29 Derivados de 4-azaindol

Country Status (21)

Country Link
US (3) US9926312B2 (es)
EP (2) EP3489237B1 (es)
JP (3) JP6517790B2 (es)
KR (1) KR102248559B1 (es)
CN (1) CN105873927B (es)
AR (1) AR097866A1 (es)
AU (1) AU2014330880B2 (es)
BR (1) BR112016007016A8 (es)
CA (1) CA2924619C (es)
CL (1) CL2016000726A1 (es)
ES (2) ES2710190T3 (es)
GB (1) GB201317363D0 (es)
HK (1) HK1223090A1 (es)
IL (1) IL244609B (es)
MX (1) MX368956B (es)
PE (1) PE20160839A1 (es)
PH (1) PH12016500529A1 (es)
RU (1) RU2688938C2 (es)
SG (1) SG11201602052YA (es)
TW (1) TW201546070A (es)
WO (1) WO2015049574A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
JP6517239B2 (ja) 2014-04-23 2019-05-22 武田薬品工業株式会社 アルツハイマー病治療のためのコリン作動性ムスカリンｍ１受容体ポジティブアロステリックモジュレーター活性としてのイソインドリン−１−オン誘導体
WO2015174534A1 (ja) 2014-05-16 2015-11-19 武田薬品工業株式会社 含窒素複素環化合物
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
DK3303331T3 (en) 2015-06-08 2019-04-23 Suven Life Sciences Ltd MUSCARIN M1 RECEPTOR-POSITIVE ALLOSTER MODULATORS
NZ740587A (en) * 2015-09-10 2019-07-26 Suven Life Sciences Ltd Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
US11111251B2 (en) * 2016-02-16 2021-09-07 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M1
US10899759B2 (en) 2016-09-30 2021-01-26 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M1
CN111212840B (zh) * 2017-10-18 2022-07-22 苏文生命科学有限公司 作为毒蕈碱m1受体正向别构调节剂的杂芳基化合物
CN111278814B (zh) * 2017-10-27 2022-10-28 苏文生命科学有限公司 作为毒蕈碱m1受体正向别构调节剂的多环酰胺
KR102347368B1 (ko) * 2020-11-03 2022-01-07 (주)케이메디켐 신규한 아자인돌 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420521D0 (en) 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
US6063930A (en) 1996-04-03 2000-05-16 Merck & Co., Inc. Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
MXPA04004711A (es) 2001-11-19 2005-08-16 Neurogen Corp Amidas del acido 1h-pirrolo(3,2-b(piridin-3-carboxilico.
GB0222743D0 (en) 2002-10-01 2002-11-06 Celltech R&D Ltd Chemical compounds
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
WO2004089415A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
WO2004089896A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS
WO2004089416A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
EP1853261B1 (de) 2005-03-03 2017-01-11 Universität des Saarlandes Selektive hemmstoffe humaner corticoidsynthasen
FR2890072A1 (fr) * 2005-09-01 2007-03-02 Fournier S A Sa Lab Nouveaux composesde pyrrolopyridine
CA2635899A1 (en) 2006-01-19 2007-07-26 Osi Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
US7964728B2 (en) 2006-07-06 2011-06-21 Solvay Pharmaceuticals B.V. Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
WO2008067566A1 (en) 2006-11-30 2008-06-05 Amira Pharmaceuticals, Inc. Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators
EA020332B1 (ru) 2007-08-10 2014-10-30 Х. Лундбекк А/С Аналоги гетероариламидов
JP5258889B2 (ja) 2007-08-29 2013-08-07 メルク・シャープ・アンド・ドーム・コーポレーション ウイルス感染症の治療のための２，３−置換アザインドール誘導体
AU2009206580A1 (en) * 2008-01-25 2009-07-30 Merck Sharp & Dohme Corp. Quinolizidinone M1 receptor positive allosteric modulators
DK2240482T3 (da) 2008-01-31 2013-10-21 Sanofi Sa Cykliske azaindol-3-carboxamider, deres fremstilling og deres anvendelse som lægemidler
WO2009121033A2 (en) 2008-03-27 2009-10-01 University Of Southern California Substituted nitrogen heterocycles and synthesis and uses thereof
WO2009121623A2 (en) 2008-04-04 2009-10-08 Summit Corporation Plc Compounds for treating muscular dystrophy
US8012992B2 (en) 2008-06-30 2011-09-06 Allergan, Inc. Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
AU2009283195A1 (en) 2008-08-18 2010-02-25 Yale University MIF modulators
WO2010033980A2 (en) 2008-09-22 2010-03-25 Isis Innovation Ltd. 4-azaindole bisphosphonates
MY162502A (en) 2008-11-20 2017-06-15 Merck Sharp & Dohme Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
BRPI0922937A2 (pt) 2008-12-05 2019-09-24 Hoffmann La Roche inibidores de pirrolopirazinil uréia quinase
EP2370407B1 (en) 2008-12-19 2014-06-18 Bristol-Myers Squibb Company Carbazole and carboline kinase inhibitors
US8486946B2 (en) 2009-02-23 2013-07-16 Merck Sharp & Dohme Corp. Pyrazolo [4,3-c] cinnolin-3-one M1 receptor positive allosteric modulators
WO2010123716A1 (en) 2009-04-20 2010-10-28 Merck Sharp & Dohme Corp. Heterocyclic fused cinnoline m1 receptor positive allosteric modulators
JP2012211085A (ja) 2009-08-12 2012-11-01 Kyowa Hakko Kirin Co Ltd ヘッジホッグシグナル阻害剤
US8816085B2 (en) * 2009-08-26 2014-08-26 Takeda Gmbh Methylpyrrolopyridinecarboxamides
AU2010286683B9 (en) 2009-08-31 2014-09-04 Merck Sharp & Dohme Llc Pyranyl aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators
EP2512245B1 (en) * 2009-12-14 2014-07-23 Merck Sharp & Dohme Corp. Pyridoquinazolinone m1 receptor positive allosteric modulators
ES2575154T3 (es) * 2009-12-17 2016-06-24 Merck Sharp & Dohme Corp. Moduladores alostéricos positivos del receptor M1 de quinolina amida
EP2515656B1 (en) 2009-12-21 2014-08-06 Merck Sharp & Dohme Corp. Aminobenzoquinazolinone m1 receptor positive allosteric modulators
RU2012131280A (ru) 2009-12-23 2014-02-10 Санофи [4-(5-аминометил-2-фторфенил)пиперидин-1-ил]-(1н-пирролопиридинил)метаноны и их синтез
US8883850B2 (en) 2010-05-28 2014-11-11 Merck Sharp & Dohme Corp. Naphthalene carboxamide M1 receptor positive allosteric modulators
EP2582241B1 (en) * 2010-06-15 2016-04-06 Merck Sharp & Dohme Corp. Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators
WO2011159554A1 (en) * 2010-06-15 2011-12-22 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide m1 receptor positive allosteric modulators
EP2588104B1 (en) 2010-07-01 2014-12-10 Merck Sharp & Dohme Corp. Isoindolone m1 receptor positive allosteric modulators
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
WO2012047702A1 (en) 2010-10-04 2012-04-12 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
EP2675893B1 (en) 2011-02-18 2019-01-09 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2012154888A1 (en) 2011-05-09 2012-11-15 Proteostasis Therapeutics, Inc. Compounds for treating protein folding disorders
EP2709621B1 (en) 2011-05-17 2016-11-02 Merck Sharp & Dohme Corp. N-linked quinolineamide m1 receptor positive allosteric modulators
WO2012158475A1 (en) 2011-05-17 2012-11-22 Merck Sharp & Dohme Corp. N-linked lactam m1 receptor positive allosteric modulators
US9284312B2 (en) * 2011-05-17 2016-03-15 Merck Sharp & Dohme Corp. N-methyl tetrahydroquinoline M1 receptor positive allosteric modulators
ES2604958T3 (es) 2011-10-28 2017-03-10 Vanderbilt University Análogos de 2-(4-heterociclilbencil)isoindolin-1-ona sustituidos como moduladores alostéricos positivos del receptor muscarínico de acetilcolina M1
US9403835B2 (en) 2011-12-22 2016-08-02 Ares Trading S.A. Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators
US9012445B2 (en) 2012-01-12 2015-04-21 Vanderbilt University Substituted 4-(1H-pyrazol-4-yl)benzyl analogues as positive allosteric modulators of mAChR M1 receptors
CN105636646B (zh) * 2013-07-17 2017-12-19 全球结核病药物研发联盟 氮杂吲哚化合物、其合成及其使用方法
TW201512197A (zh) * 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
WO2015044072A1 (en) * 2013-09-27 2015-04-02 F. Hoffmann-La Roche Ag Indol and indazol derivatives
GB201317363D0 (en) * 2013-10-01 2013-11-13 Eisai Ltd Novel compounds

Also Published As

Publication number Publication date
US20180208593A1 (en) 2018-07-26
CA2924619A1 (en) 2015-04-09
GB201317363D0 (en) 2013-11-13
CN105873927B (zh) 2017-11-28
MX368956B (es) 2019-10-23
CN105873927A (zh) 2016-08-17
ES2710190T3 (es) 2019-04-23
HK1223090A1 (zh) 2017-07-21
KR102248559B1 (ko) 2021-05-04
BR112016007016A8 (pt) 2020-02-27
IL244609B (en) 2019-12-31
KR20160072133A (ko) 2016-06-22
PE20160839A1 (es) 2016-08-20
EP3489237B1 (en) 2020-05-13
EP3489237A1 (en) 2019-05-29
WO2015049574A1 (en) 2015-04-09
US20160244445A1 (en) 2016-08-25
US10072005B2 (en) 2018-09-11
AR097866A1 (es) 2016-04-20
RU2016116775A3 (es) 2018-06-27
AU2014330880A1 (en) 2016-04-07
JP2020143100A (ja) 2020-09-10
US9926312B2 (en) 2018-03-27
TW201546070A (zh) 2015-12-16
RU2016116775A (ru) 2017-11-09
BR112016007016A2 (pt) 2017-08-01
ES2807221T3 (es) 2021-02-22
JP6517790B2 (ja) 2019-05-22
JP6899944B2 (ja) 2021-07-07
CA2924619C (en) 2021-12-07
PH12016500529A1 (en) 2016-05-16
IL244609A0 (en) 2016-04-21
AU2014330880B2 (en) 2019-01-31
SG11201602052YA (en) 2016-04-28
JP2016531890A (ja) 2016-10-13
JP2019112433A (ja) 2019-07-11
EP3052496B1 (en) 2018-11-28
US20150094328A1 (en) 2015-04-02
RU2688938C2 (ru) 2019-05-23
EP3052496A1 (en) 2016-08-10
MX2016004014A (es) 2016-09-21

Similar Documents

Publication Publication Date Title
CL2016000726A1 (es) Derivados de 4-azaindol
CY1123645T1 (el) Δικυκλικα παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
CL2015001733A1 (es) Compuestos derivados de lactamas fusionadas de arilo y heteroarilo, moduladores de ezh2; composicion farmaceutica que los comprende; uso del compuesto para el tratamiento del cancer.
CL2016003246A1 (es) Compuestos de dihidroisoquinolinona sustituida
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
CL2018001217A1 (es) Antagonistas del receptor muscarinico 4 y metodos de uso.
DK3313838T3 (da) Polycykliske amidderivater som cdk9-inhibitorer
EA201891209A1 (ru) Модуляторы хемокиновых рецепторов
CR20180564A (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que lo contienen
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2015003147A1 (es) Compuestos de biheteroarilo y usos de los mismos
CL2015002855A1 (es) Derivados de oxopiridina sustituida.
CL2017003127A1 (es) Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores de receptor muscarinico m1 colinergico.
CR20160296A (es) Benzamidas sustituidas y métodos para usarlas
DK3357919T3 (da) Aromatiske heterocykliske forbindelser som antiinflammatoriske forbindelser
CL2018002335A1 (es) Moduladores alostéricos positivos del receptor de acetilcolina muscarínico m1
CO2019005059A2 (es) Inhibidores de magl
BR112016021962A2 (pt) Compostos, composição farmacêutica e seus usos como moduladores de ror gama
CL2018000696A1 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue.
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CO2019005038A2 (es) Inhibidores de magl
CL2019001336A1 (es) Inhibidores de la magl.
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
CL2015003635A1 (es) Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos útiles como inhibidores de quinasa.
UY36654A (es) Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen